Investigating the Effect of Alpha-ketoglutarate on Survival and Proliferation of Ovarian Cancer Cells
Subject Areas : Journal of Animal Biology
Hossein Beiranvand
1
(Department of Animal Sciences and Marine Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran)
MAHMOOD TALKHABI
2
(Department of Animal Sciences and Marine Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran)
Monireh Mahmoodi
3
(Department of Biology, Faculty of Science, Arak University, Arak 384817758, Iran.)
Ghamartaj Hossein
4
(Developmental Biology Laboratory, Department of Animal Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran)
Keywords: Ovarian cancer, OVCAR-3 cell line, Alpha-ketoglutarate, Viability, Colonization, Migration,
Abstract :
Ovarian cancer is the third most common cancer in women. Recent studies have shown that Alpha-ketoglutarate (AKG) has an important therapeutic role in heart and nervous diseases and cancers. In the curreny study, ovarian cancer cells (OVCAR-3 cell line) were obtained from the University of Tehran at the second passage, and cultured in a complete culture medium (1640 RPMI medium containing 10% FBS and 1% penicillin / streptomycin antibiotic). MTT technique was used to evaluate cellular viability. Also, the doubling time of cell population, colony formation and migration of cells were investigated using appropriate methods. MTT assay showed that treatment of cells with AKG decreases viability in a concentration-dependent manner. Based on the MTT assay results, 120 and 60 μM AKG were selected for the next expreimets. Evaluation of population doubling time showed that both used concentrations significantly reduce cell growth (P<0.05). Colony forming assay showed that 120 and 60 μM of AKG caused a significant decrease in the number of OVCAR-3 colonies (P<0.01). The study of cell migration showed that the treatment of cells with the mentioned concentrations significantly reduces the migration of cells to the scratch area (P<0.01). The results obtained from this study show that AKG reduces the viability of ovarian cancer cells and has anti-proliferative and anti-migratory effects for this cancer cells. It seems that the use of AKG along with other existing treatments can become an helpful approach for better control and treatment of ovarian cancer.
1. Anand P., Kunnumakara A.B., Sundaram C., Harikumar K.B., Tharakan S.T., Lai O.S., Sung B., Aggarwal B.B., 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical Research, 25: 2097-2116.
2. Atlante S., Visintin A., Marini E., Savoia M., Dianzani C., Giorgis M., Sürün D., Maione F., Schnütgen F., Farsetti A., Zeiher A.M. 2018. α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell Death and Disease, 9(7):756.
3. Bast Jr R.C., Hennessy B. Mills G.B. 2009. The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer, 9(6):415-428.
4. Bradbury A., O’Donnell R., Drew Y., Curtin N.J., Sharma Saha S. 2020. Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting. Cancers, 12(7):1939.
5. Cheng Z.G., Zhang G.D., Shi P.Q., Du B.S. 2013. Expression and antioxidation of Nrf2/ARE pathway in traumatic brain injury. Asian Pacific Journal of Tropical Medicine, 6(4):305-310.
6. Duan L., Perez R.E., Maki C.G. 2019. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biology and Therapy, 20(3):252-260.
7. Greilberger J., Herwig R., Greilberger M., Stiegler P., Wintersteiger R. 2021. Alpha-Ketoglutarate and 5-HMF: A potential anti-tumoral combination against leukemia cells. Antioxidants, 10(11): p.1804.
8. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., Whang-Peng J., Rogan A.M., Green W.R., Ozols R.F. 1983. Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Research, 43(11):5379-5389.
9. Harrison A.P., Pierzynowski S.G. 2008. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption/metabolism, muscle performance, kidney function, bone formation and cancerogenesis, all viewed from a healthy ageing perspective state of the art-review article. Journal of Physiology and Pharmacology, 59(Suppl 1):91-106.
10. Kaławaj K., Sławińska-Brych A., Mizerska-Kowalska M., Żurek A., Bojarska-Junak A., Kandefer-Szerszeń M., Zdzisińska B. 2020. Alpha ketoglutarate exerts in vitro anti-osteosarcoma effects through inhibition of cell proliferation, induction of apoptosis via the JNK and Caspase 9-Dependent mechanism, and suppression of TGF-β and VEGF production and metastatic potential of cells. International Journal of Molecular Sciences, 21(24):9406.
11. Katewa S.D., Kapahi P. 2011. Role of TOR signaling in aging and related biological processes in Drosophila melanogaster. Experimental Gerontology, 46(5):382-390.
12. Long L.H., Halliwell B. 2011. Artefacts in cell culture: α-Ketoglutarate can scavenge hydrogen peroxide generated by ascorbate and epigallocatechin gallate in cell culture media. Biochemical and Biophysical Research Communications, 406(1):20-24.
13. Maryam B., Fatemeh S., Nourossadat K., Saeideh N., Giti O. 2022. Women's awareness of ovarian cancer risk factors and symptoms in Western Iran in 2020–2021. BMC Women's Health, 22(1):192.
14. Matsumoto K., Imagawa S., Obara N., Suzuki N., Takahashi S., Nagasawa T., Yamamoto, M., 2006. 2‐oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia‐inducible factor‐1α and inhibits angiogenesis. Journal of Cellular Physiology, 209(2):333-340.
15. McLemore M.R., Miaskowski C., Aouizerat B.E., Chen L.M., Dodd M.J. 2009. Epidemiologic and genetic factors associated with ovarian cancer. Cancer Nursing, 32(4):281.
16. Meeran S.M., Katiyar, S.K. 2008. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Frontiers in Bioscience: a Journal and Virtual Library, 13:2191.
17. Naeini S.H., Mavaddatiyan L., Kalkhoran Z.R., Taherkhani S., Talkhabi M. 2023. Alpha-ketoglutarate as a potent regulator for lifespan and healthspan: Evidences and perspectives. Experimental Gerontology, 175:112154.
18. Rebbeck T.R., Kauff N.D., Domchek S.M. 2009. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2):80-87.
19. Rzeski W., Walczak K., Juszczak M., Langner E., PoŻarowski P., Kandefer-Szerszeń M., Pierzynowski S.G. 2012. Alpha-ketoglutarate (AKG) inhibits proliferation of colon adenocarcinoma cells in normoxic conditions. Scandinavian Journal of Gastroenterology, 47(5):565-571.
20. Sam Daliri F., Talkhabi M., Toolabi N., Attari F., Kehtari M. 2023. Investigation of the Effect of Conditioned Media of Mesenchymal Stem Cells Treated with Ascorbic Acid on Proliferative Behavior of Breast Cancer Cells. Journal of Animal Biology, 15(2):233-245.
21. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3):209-249.
22. Tran T.Q., Hanse E.A., Habowski A.N., Li H., Ishak Gabra M.B., Yang Y., Lowman X.H., Ooi A.M., Liao S.Y., Edwards R.A. and Waterman, M.L., 2020. α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer. Nature Cancer, 1(3):345-358.
23. Tseng C.W., Kuo W.H., Chan S.H., Chan H.L., Chang K.J. and Wang L.H., 2018. Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the α-ketoglutarate signaling pathway. Cancer Research, 78(11):2799-2812.
24. Vaisman N., Arber N., 2002. The role of nutrition and chemoprevention in colorectal cancer: from observations to expectations. Best Practice and Research Clinical Gastroenterology, 16(2):201-217.